Ed Cinca

Ed is a recognized leader in the pharmaceutical industry, with diversified, progressive experience centered around small to multibillion-dollar product launches and commercialization. He brings with him 20 years of experience in pharma and biotech with strong emphasis on business strategy, innovation, execution, and transformation. Ed’s most recent role was as SVP/GM at Currax Pharmaceuticals, which is an industry leader in the treatment of obesity and smoking cessation. In this capacity, he led the relaunch of a mature brand leading to new market inroads, while simultaneously planning for the commercialization of a new product. Before that, he had a very successful career with Novo Nordisk, Inc. (NNI) serving as an Leadership team member and Vice President, Head of Cardiometabolic portfolio where he directed the launches of Ozempic, Rybelsus and Wegovy.